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ABSTRACT Diabetic retinopathy is a leading cause of
adult vision loss and blindness. Much of the retinal damage
that characterizes the disease results from retinal vascular
leakage and nonperfusion. This study shows that diabetic
retinal vascular leakage and nonperfusion are temporally and
spatially associated with retinal leukocyte stasis (leukostasis)
in the rat model of streptozotocin-induced diabetes. Retinal
leukostasis increases within days of developing diabetes and
correlates with the increased expression of retinal intercellu-
lar adhesion molecule-1 (ICAM-1). ICAM-1 blockade with a
mAb prevents diabetic retinal leukostasis and vascular leak-
age by 48.5% and 85.6%, respectively. These data identify the
causal role of leukocytes in the pathogenesis of diabetic
retinopathy and establish the potential utility of ICAM-1
inhibition as a therapeutic strategy for the prevention of
diabetic retinopathy.
Although retinal vascular leakage and nonperfusion are rec-
ognized as two major complications of diabetes, their patho-
genesis remains poorly understood. Leukocytes may be in-
volved in the genesis of these complications. Diabetic retinop-
athy generally is not considered an inflammatory disease, but
the retinal vasculature of humans (1) and rodents (2, 3) with
diabetes mellitus contains increased numbers of leukocytes.
Many of these leukocytes are static (2, 3). The causes and
consequences of this phenomenon are largely unknown. In-
tercellular adhesion molecule-1 (ICAM-1) is a peptide known
to mediate leukocyte adhesion and transmigration (4, 5).
ICAM-1 may be operative in the stasis observed in diabetic
retinopathy, because ICAM-1 immunoreactivity is increased
in the diabetic retinal vasculature of humans (1). However,
little is known about the direct pathogenetic role of ICAM-1
in diabetic retinopathy. This study investigated the mecha-
nisms of diabetic retinal leukocyte stasis (leukostasis) and the
role leukocytes play in the development of two sight-
threatening complications, vascular leakage and capillary non-
perfusion.
EXPERIMENTAL PROCEDURES
Animals and Experimental Diabetes. All animal experi-
ments followed the guidelines of the Association for Research
in Vision and Ophthalmology and were approved by the
Animal Care and Use Committees of the Children’s Hospital
and Joslin Diabetes Center. Long–Evans rats weighing ap-
proximately 200 g received a single 60 mgykg injection of
streptozotocin (Sigma) in 10 mM citrate buffer (pH 4.5) after
an overnight fast. Control nondiabetic animals received citrate
buffer alone. Animals with blood glucose levels greater than
250 mgydl 24 h later were considered diabetic. Blood pressure
was measured by using a noninvasive cuff sensor and moni-
toring system (Ueda Electronics, Tokyo). Blood treated with
the anticoagulant EDTA was drawn from the abdominal aorta
of each rat after the experiment. The blood sample was
analyzed with a hematology analyzer. The rats were fed on
standard laboratory chow and were allowed free access to
water in an air-conditioned room with a 12-h lighty12-h dark
cycle until they were used for the experiments.
Acridine Orange Leukocyte Fluorography (AOLF) and
Fluorescein Angiography. Leukocyte dynamics in the retina
were studied with AOLF (3, 6, 7). Intravenous injection of
acridine orange causes leukocytes and endothelial cells to
fluoresce through the noncovalent binding of the molecule to
double-stranded nucleic acid. When a scanning laser ophthal-
moscope is used, retinal leukocytes within blood vessels can be
visualized in vivo. Static leukocytes in the capillary bed can be
observed 20 min after acridine-orange injection (3, 6). Imme-
diately after observing and recording the static leukocytes,
f luorescein angiography was performed to study the relation-
ship between static leukocytes and retinal vasculature.
For the administration of acridine orange or sodium fluo-
rescein dye, all rats had a heparin-lock catheter surgically
implanted in the right jugular vein 24 h before AOLF and
fluorescein angiography were performed. The catheter was
externalized subcutaneously to the back of the neck. The rats
were anesthetized for this procedure with xylazine hydrochlo-
ride (4 mgykg; Phoenix Pharmaceutical, St. Joseph, MO) and
ketamine hydrochloride (25 mgykg; Parke-Davis). Immedi-
ately before AOLF, each rat was again anesthetized, and the
pupil of the left eye was dilated with 1% tropicamide (Alcon
Laboratories, Humancao, Puerto Rico) to observe leukocyte
dynamics. A focused image of the peripapillary fundus of the
left eye was obtained with a scanning laser ophthalmoscope
(Rodenstock Instruments, Munich). Acridine orange (Sigma)
was dissolved in sterile saline (1.0 mgyml), and 3 mgykg was
injected through the jugular vein catheter at a rate of 1 mlymin.
The fundus was observed with the scanning laser ophthalmo-
scope by using the argon blue laser as the illumination source
and the standard fluorescein angiography filter in the 40° field
setting for 1 min. After 20 min, the fundus was observed again
to evaluate leukostasis in the retina. Immediately after eval-
uating retinal leukostasis, 20 ml of 1% sodium fluorescein dye
was injected into the jugular vein catheter. The images were
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recorded on a videotape at the rate of 30 frames per second.
The video recordings were analyzed on a computer equipped
with a video digitizer (Radius, San Jose, CA) that digitizes the
video image in real time (30 frames per second) to 640 3 480
pixels with an intensity resolution of 256 steps. For evaluating
retinal leukostasis, an observation area around the optic disc
measuring 10 disc diameters in diameter was determined by
drawing a polygon surrounded by the adjacent major retinal
vessels. The area was measured in pixels, and the density of
trapped leukocytes was calculated by dividing the number of
trapped leukocytes, which were recognized as fluorescent dots,
by the area of the observation region. The densities of leuko-
cytes were calculated generally in eight peripapillary observa-
tion areas, and an average density was obtained by averaging
the eight density values.
Isotope Dilution Technique. Vascular leakage was quanti-
fied by using an isotope dilution technique based on the
injection of BSA labeled with two different iodine isotopes, 125I
and 131I (8, 9). Briefly, purified monomer BSA (1 mg) was
iodinated with 1 mCi of 131I or 125I by using the iodogen
method. Polyethylene tubing (0.58-mm internal diameter) was
used to cannulate the right jugular vein and the left or right
iliac artery. The tubing was filled with heparinized saline. The
right jugular vein cannula was used for tracer injection. The
iliac artery cannula was connected to a 1-ml syringe attached
to a Harvard Bioscience model PHD 2000 constant-
withdrawal pump preset to withdraw at a constant rate of 0.055
mlymin. At time 0, [125I]BSA (50 million cpm in 0.3 ml of
saline) was injected into the jugular vein, and the withdrawal
pump was started. At the 8-min mark, 0.2 ml (50 million cpm)
of [131I]BSA was injected. At the 10-min mark, the heart was
excised; the withdrawal pump was stopped; and the retina was
quickly dissected and sampled for g-spectrometry. Tissue and
arterial samples were weighed and counted in a g-spectrom-
eter (Beckman Instruments 5500). The data were corrected for
background, and a quantitative index of [125I]BSA tissue
clearance was calculated as described (8, 9) and expressed as
micrograms of plasma per tissue wet weight21 per minute21.
Briefly, [125I]BSA tissue activity was corrected for [125I]BSA
contained within the tissue vasculature by multiplying
[125I]BSA activity in the tissue by the ratio of [125I]BSAy
[131I]BSA in the arterial plasma sample obtained at the end of
the experiment. The vascular-corrected [125I]BSA activity was
divided by the time-averaged [125I]BSA plasma activity (ob-
tained from a well mixed sample of plasma taken from the
withdrawal syringe) and by the tracer circulation time (10 min)
and then normalized per gram of tissue wet weight.
Ribonuclease Protection Assay. The retinas were excised
gently, cut at the optic disc after enucleation, and frozen
immediately in liquid nitrogen. Total RNA was isolated from
rat retinas according to the acid guanidinium thiocyanate-
phenol-chloroform extraction method. A 425-bp EcoRI–
BamHI fragment of rat ICAM-1 cDNA was prepared by
reverse transcription–PCR and cloned into pBluescript II
KS(2) vector. A 472-nt antisense riboprobe was prepared by
in vitro transcription (Promega) of linearized plasmid DNA
with T7 RNA polymerase in the presence of [32P]dUTP. The
sequence of the cloned cDNA was verified by DNA sequenc-
ing. Total cellular RNA (20 mg) was used for ribonuclease
protection assays. All samples were simultaneously hybridized
with an 18S riboprobe (Ambion, Austin, TX) to normalize for
variations in loading and recovery of RNA. Protected frag-
ments were separated on a gel of 5% acrylamidey8 M ureay13
Tris-borate-EDTA and quantified with a PhosphorImager
(Molecular Dynamics).
ICAM-1 Blockade. Confirmed diabetic animals received
intraperitoneal injections of 3 mgykg or 5 mgykg rat ICAM-1
neutralizing antibody (1A29; R & D Systems) or 5 mgykg
normal mouse IgG1 (R & D Systems) in sterile PBS 24 h after
streptozotocin injection. The animals were treated three times
per week. Retinal leukostasis and vascular leakage were
studied 1 week after diabetes induction.
Statistical Analysis. All results are expressed as means 6
SD. The data were compared by ANOVA with post hoc
comparisons tested by using Fisher’s protected least significant
difference procedure. Differences were considered statistically
significant when P values were less than 0.05.
RESULTS AND DISCUSSION
Time-Course Changes of Retinal Leukostasis and Vascular
Leakage After Diabetes Induction. Retinal leukostasis was
quantified in Long–Evans rats. Diabetic rats, like humans with
diabetes, develop retinal nonperfusion and increased vascular
permeability. By using AOLF, a time-course analysis showed
that retinal leukostasis increased 1.9-fold as early as 3 days
after diabetes induction (n 5 5; P , 0.05; Fig. 1A). After 1
week of diabetes, retinal leukostasis was 3.2-fold higher than
it was in nondiabetic controls (n 5 5; P , 0.0001). This finding
remained unchanged in degree for 3 additional weeks (n 5 5;
P , 0.0001; Fig. 1 A). Reliable leukostasis quantitation beyond
the 4-week time point was precluded by cataract formation.
Leukocyte adhesion to endothelial cells can trigger the
disorganization of endothelial cell adherens and tight junctions
(10, 11) as well as vascular leakage (12). To determine whether
diabetic retinal leukostasis was correlated with blood–retinal
barrier breakdown, retinal albumin permeation was quantified
(Fig. 1B). Retinal albumin permeation characterizes human
and rodent diabetic retinopathy (8, 13) and can be quantified
FIG. 1. Time course of diabetic retinal leukostasis and vascular
leakage. (A) Leukostasis was quantified serially by using AOLF.
Nondiabetic animals (day 0) and animals with streptozotocin-induced
diabetes of varying duration were studied. (B) Radioactive albumin
permeation into retinal tissue was quantitated at the same time points
by using the isotope dilution technique. All data show the means 6 SD.
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sensitively by using the isotope dilution technique (8, 9). A
time-course analysis in diabetic rats revealed a 2.9-fold (n 5 8;
P , 0.0001) and 10.7-fold (n 5 8; P , 0.0001) increase in
albumin permeation after 1 and 4 weeks of diabetes (Fig. 1B).
The breakdown of the blood–retinal barrier followed the onset
of diabetes-associated retinal leukostasis.
Leukocyte-Induced Nonperfusion and Reperfusion in Ret-
inal Capillaries. To characterize the diabetic retinal leukosta-
sis further, serial AOLF and fluorescein angiography studies
were performed. These studies indicated that the individual
leukocytes observed with AOLF are in flux, even though the
overall degree of leukostasis is constant (Fig. 2). The static
retinal leukocytes observed 7 days after the induction of
diabetes are topographically distinct from those observed 24 h
later. Furthermore, a fraction of the leukocytes are in the
extravascular space, a result consistent with their rapid trans-
migration after dye labeling.
Fluorescein angiography and AOLF were also used to study
retinal nonperfusion. These studies identified static leukocytes
directly associated with areas of downstream nonperfusion
(Figs. 2 and 3). The nonperfused capillaries were patent before
the onset of the leukostasis, suggesting a causal relationship.
As the leukocyte(s) disappeared, the capillaries either reper-
fused or remained closed (Fig. 3). Reperfusion has been
observed in human diabetic retinopathy, but the mechanism
has remained unexplained (14–16). These observations sug-
gest the phenomenon may result, in part, from retinal leuko-
stasis.
ICAM-1 Gene Expression in Diabetic Retina. To determine
whether retinal ICAM-1 expression increases in association
FIG. 2. Static leukocytes are in flux, block capillary flow, and transmigrate. Serial AOLF of static leukocytes in the same retinal area after 7
(A) and 8 (C) days of diabetes shows their complete replacement within a 24-h period. The arrows point to a static leukocyte (A and B) that seems
to have transmigrated (B). After 1 day, AOLF and fluorescein angiography show that the leukocyte has disappeared (C and D). The arrowheads
show a patent capillary (B) that subsequently becomes obstructed by a static leukocyte 24 h later (C and D). (Bars 5 100 mm; 3.2 pixel 5 1 mm.)
Table 1. Characteristics of control, diabetic, mouse IgG1-treated diabetic, and anti-ICAM-1 mAb-treated diabetic rats
Characteristic Control Diabetes
Diabetes 1 5
mgykg mouse
IgG1
Diabetes 1 anti-ICAM-1 mAb
3 mgykg 5 mgykg
Number 6 7 5 5 5
Body weight, g 271 6 12 240 6 12* 235 6 9* 238 6 6* 239 6 12*
Plasma glucose, mgydl 123 6 19 332 6 35* 316 6 61* 351 6 83* 373 6 68*
Blood pressure, mmHg 111 6 6 104 6 12 109 6 14 105 6 9 105 6 10
Leukocyte count, 3103yml 6.1 6 1.6 5.0 6 1.5† 5.3 6 0.8† 6.9 6 1.4 7.4 6 2.3
Values are means 6 SD; 1 mmHg 5 133 Pa.
*P , 0.0001 vs. control rats; †P , 0.05 vs. 5 mgykg anti-ICAM-1 mAb-treated diabetic rats.
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with diabetic retinal leukostasis, ICAM-1 mRNA levels were
quantified by using the ribonuclease protection assay. Retinas
analyzed 3 days after diabetes induction had ICAM-1 mRNA
levels that were 1.5-fold higher than in nondiabetic controls,
but this increase was not statistically significant (n 5 5; P .
0.05; Fig. 4). After 1 week of diabetes, the retinal ICAM-1
levels were 2.2-fold greater, a significant increase when com-
pared with nondiabetic controls (n 5 4; P , 0.05). The
ICAM-1 increase coincided temporally with the development
of diabetic retinal leukostasis and blood–retinal barrier break-
down.
An Anti-ICAM-1 mAb Prevents Leukostasis and Vascular
Leakage in Diabetic Retina. To assess whether ICAM-1 me-
diates diabetic retinal leukostasis, a well characterized
ICAM-1 neutralizing antibody (1A29; ref. 17–19) was used for
in vivo adhesion blockade experiments. Animals received
either 3 or 5 mgykg intraperitoneal injections of the ICAM-1
antibody three times weekly. Control diabetic animals received
an equivalent amount of a nonimmune isotype control anti-
body. All animals were analyzed 1 week after diabetes induc-
tion. The results showed that the ICAM-1 antibody blocked
diabetes-induced leukostasis by 40.9% (3 mgykg; n 5 5; P ,
0.01) and 48.5% (5 mgykg; n 5 5; P , 0.001; Figs. 5 and 6A).
The peripheral leukocyte counts at 1 week increased by 40%
(5 mgykg; n 5 5; P , 0.05) compared with the control
antibody-treated animals, a result consistent with successful
FIG. 3. Leukocyte-induced nonperfusion and reperfusion. Serial studies were completed 1 (A and B), 2 (C and D), and 4 (E and F) weeks after
diabetes induction by using both AOLF (A, C, and E) and fluorescein angiography (B, D, and F). The arrows show a patent capillary (B) that
subsequently becomes occluded downstream from a static leukocyte (C and D) and then opens up when the leukocyte disappears (E and F). The
arrowheads show a patent capillary (B) that becomes occluded downstream from a static leukocyte (C and D) and then remains closed after the
leukocyte has disappeared (E and F). (Bars 5 100 mm; 3.2 pixel 5 1 mm.)
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systemic ICAM-1 blockade (Table 1). Body weight, plasma
glucose, and blood pressure were unchanged in all diabetic
groups (Table 1).
The effect of the ICAM-1 inhibition on blood–retinal bar-
rier breakdown was tested by using the same antibody. Animals
receiving 3 and 5 mgykg of the anti-ICAM-1 antibody had
63.5% (3 mgykg; n 5 4; P , 0.0001) and 85.6% (5 mgykg; n 5
4; P , 0.0001) less retinal albumin permeation at 1 week (Fig.
6B). The results suggest that the ICAM-1-dependent compo-
nent of the leukostasis is largely responsible for the blood–
retinal barrier breakdown.
Conclusions. These data indicate that retinal leukostasis is
a very early event in diabetic retinopathy with important
functional consequences. Both retinal vascular leakage and
nonperfusion seem to follow its development. The inhibition
of ICAM-1 bioactivity blocks diabetic retinal leukostasis and
potently prevents blood–retinal barrier breakdown. Although
not directly tested here, leukostasis seems to be associated with
the development of vascular nonperfusion, and thus its inhi-
bition may also prevent capillary dropout. Indeed, activated
leukocytes are increased in diabetes (20) and leukocytes have
been associated with capillary loss in the diabetic choroid (21).
The inciting stimulus for ICAM-1 up-regulation remains un-
known; however, it is not likely to be endothelial cell death,
because ICAM-1 inhibition largely maintains the blood–
retinal barrier. Taken together, our data show that ICAM-1-
mediated leukostasis is increased in the retinal vasculature
very early in diabetes and accounts for the majority of diabetes-
FIG. 5. In vivo retinal leukostasis inhibition. Representative retinal
leukostasis observed with AOLF in nondiabetic (A), diabetic (B),
diabetic 1 5 mgykg mouse control IgG1 (C), and diabetic 1 5 mgykg
anti-ICAM-1 mAb-treated animals (D). (Bars 5 100 mm; 3.2 pixel 5
1 mm.)
FIG. 4. ICAM-1 gene expression in diabetic retina. (A) The
ribonuclease protection assay shows that retinal ICAM-1 levels were
increased significantly 7 days after diabetes induction. Each lane shows
the signal from the two retinas of a single animal. The lane labeled
‘‘Probes’’ shows a 100-fold dilution of the full-length ICAM-1 and 18S
riboprobes. The lanes labeled ‘‘RNase - (0.1)’’ and ‘‘RNase - (0.01)’’
show the 10-fold and 100-fold dilutions, respectively, of the full-length
riboprobes without sample or RNase. (B) When normalized to 18S
RNA, the retinal ICAM-1 levels after 7 days of diabetes were 2.2-fold
higher (n 5 4; P , 0.05) than in the nondiabetic controls. NS 5 not
significant.
FIG. 6. Effect of anti-ICAM-1 mAb on leukostasis and vascular
leakage in diabetic retina. When ICAM-1 bioactivity was inhibited via
systemic administration of the ICAM-1 neutralizing antibody, retinal
leukostasis (A) and albumin permeation (B) were decreased 48.5% (5
mgykg; n 5 5; P , 0.001) and 85.6% (5 mgykg; n 5 4; P , 0.0001),
respectively. NS 5 not significant.
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associated retinal vascular leakage. Thus, these data implicate
ICAM-1 as a potential therapeutic target for the prevention of
many of the sight-threatening retinal abnormalities associated
with diabetes.
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